Patents by Inventor Victor Pribluda

Victor Pribluda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Estradiol derivatives
    Publication number: 20070135400
    Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula: wherein the variables are defined in the specification.
    Type: Application
    Filed: February 2, 2007
    Publication date: June 14, 2007
    Inventors: Gregory Agoston, Theresa LaVallee, Victor Pribluda, Jamshed Shah, Anthony Treston
  • Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
    Publication number: 20070105903
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substituted thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
    Type: Application
    Filed: August 29, 2006
    Publication date: May 10, 2007
    Inventors: Anthony Treston, Jamshed Shah, Robert D'Amato, Barry Conner, Kimberly Hunsucker, John Rougas, Glenn Swartz, Victor Pribluda
  • Methods of treating disease states using antiangiogenic agents
    Publication number: 20070010505
    Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula: wherein the variables are defined in the specification.
    Type: Application
    Filed: September 12, 2006
    Publication date: January 11, 2007
    Inventors: Gregory Agoston, Theresa LaVallee, Victor Pribluda, Jamshed Shah, Anthony Treston
  • Use of nitrogen substituted thalidomide analogs for the treatment of macular degenerator
    Patent number: 7153867
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substituted thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: December 26, 2006
    Assignee: Celgene Corporation
    Inventors: Jamshed H. Shah, Barry P. Conner, Glenn M. Swartz, Kimberly A. Hunsucker, John Rougas, Robert J. D'Amato, Victor Pribluda, Anthony Treston
  • Compositions and methods comprising protein activated receptor antagonists
    Publication number: 20060142203
    Abstract: Compositions and methods comprising protein activated receptor antagonists are provided More particularly, the present invention relates to the use of proteins, peptides and biomolecules that bind to protein activated receptor 2, and inhibit the processes associated with the activation of that receptor. More specifically, the present invention provides novel compositions and methods for the treatment of disorders and diseases such as those associated with abnormal cellular proliferation, angiogenesis, inflammation and cancer.
    Type: Application
    Filed: June 26, 2003
    Publication date: June 29, 2006
    Inventors: Todd Hembrough, Victor Pribluda
  • Antiangiogenic agents
    Publication number: 20060135796
    Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: wherein the variables are defined in the specification.
    Type: Application
    Filed: February 6, 2006
    Publication date: June 22, 2006
    Inventors: Gregory Agoston, Victor Pribluda, Anthony Treston, Shawn Green
  • Antiangiogenic agents
    Patent number: 6995278
    Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: wherein the variables are defined in the specification.
    Type: Grant
    Filed: February 8, 2001
    Date of Patent: February 7, 2006
    Assignee: Entre Med, Inc.
    Inventors: Gregory E. Agoston, Victor Pribluda, Anthony M. Treston, Shawn J. Green
  • Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
    Publication number: 20060025329
    Abstract: Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise a naturally occurring or synthetic protein, peptide, or protein fragment containing all or an active portion of the C-terminal portion of proteinase inhibitors such as TFPI. The methods involve administering to a human or animal the composition described herein in a dosage sufficient to inhibit cell proliferation, particularly endothelial cell proliferation. The methods are useful for treating diseases and processes mediated by undesired and uncontrolled cell proliferation, such as cancer, particularly by inhibiting angiogenesis. Administration of the composition to a human or animal having prevascularized, metastasized tumors is useful for preventing the growth or expansion of such tumors.
    Type: Application
    Filed: July 18, 2005
    Publication date: February 2, 2006
    Inventors: Todd Hembrough, Victor Pribluda, Adonia Papathanassiu, Shawn Green
  • Antiangiogenic agents
    Publication number: 20050192258
    Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: wherein the variables are defined in the specification.
    Type: Application
    Filed: April 29, 2005
    Publication date: September 1, 2005
    Inventors: Gregory Agoston, Jamshed Shah, Kimberly Hunsucker, Victor Pribluda, Theresa LaVallee, Shawn Green, Christopher Herbstritt, Xiaoguo Zhan, Anthony Treston
  • Antiangiogenic agents
    Publication number: 20050014737
    Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula: wherein the variables are defined in the specification.
    Type: Application
    Filed: May 28, 2004
    Publication date: January 20, 2005
    Inventors: Gregory Agoston, Theresa LaVallee, Victor Pribluda, Jamshed Shah, Anthony Treston
  • Compositions and methods comprising protein activated receptor antagonists
    Publication number: 20040266687
    Abstract: Compositions and methods comprising protein activated receptor antagonists are provided More particularly, the present invention relates to the use of proteins, peptides and biomolecules that bind to protein activated receptor 2, and inhibit the processes associated with the activation of that receptor. More specifically, the present invention provides novel compositions and methods for the treatment of disorders and diseases such as those associated with abnormal cellular proliferation, angiogenesis, inflammation and cancer.
    Type: Application
    Filed: April 27, 2004
    Publication date: December 30, 2004
    Inventors: Todd Hembrough, Victor Pribluda
  • Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
    Publication number: 20030139451
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substituted thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
    Type: Application
    Filed: August 6, 2002
    Publication date: July 24, 2003
    Inventors: Jamshed H. Shah, Barry P. Conner, Glenn M. Swartz, Kimberly A. Hunsucker, John Rougas, Robert J. D'Amato, Victor Pribluda, Anthony Treston
  • Antiangiogenic agents
    Publication number: 20020147183
    Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula: 1
    Type: Application
    Filed: February 8, 2001
    Publication date: October 10, 2002
    Inventors: Gregory E. Agoston, Victor Pribluda, Anthony M. Treston, Shawn J. Green